dornase alfa (pulmozyme) Report issue

Biologics Recombinant protein Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW
  • Now
Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis. It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions. It is produced in Chinese hamster ovary cells.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$24.7698

United States

$44.5308 - $679.1220
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

deanase | deoxyribonuclease | deoxyribonuclease (human clone 18-1 protein moiety) | desoxyribonuclease | dornase | dornase alfa | dornase alfa (desoxyribonuclease) | dornase alfa (genetical recombination) | dornase alfa, recombinant | dornase alpha | human dnase-1 | pulmozyme | recombinant deoxyribonuclease | recombinant deoxyribonuclease (dnase) | recombinant human deoxyribonuclease i | recombinant human dnase | rhdnase

Organizations (59)

Research & Development (59)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (28)

Approved Indications (1)


 

Cystic Fibrosis

Experimental Indications - Clinical Trial Phases 1-4 (28)


 

Asthma (Phase 2)

Cough (Phase 1)

COVID-19 (Phase 4)

Cystic Fibrosis ()

Dry Eye Syndromes (Phase 1/Phase 2)

Empyema (Phase 3)

Empyema, Pleural (Phase 3)

Fibrosis (Phase 3)

Graft vs Host Disease (Phase 1/Phase 2)

Head and Neck Neoplasms (Early Phase 1)

Healthy Volunteers (Phase 1)

Hypoxia (Phase 2)

Infections (Phase 4)

Inflammation (Phase 2)

Ischemic Stroke (Phase 2)

Lung Transplantation (Phase 2)

Multiple Trauma (Phase 3)

Neoplasm Metastasis (Phase 1)

Otitis Media (Phase 4)

Peritoneal Dialysis (Phase 1)

Peritoneal Dialysis, Continuous Ambulatory (Phase 1)

Pulmonary Atelectasis (Phase 4)

Respiratory Distress Syndrome (Phase 3)

Respiratory Tract Infections (Phase 2)

Severe Acute Respiratory Syndrome (Phase 3)

Sinusitis (Phase 3)

Sjogren's Syndrome (Phase 1)

Ventilation (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 46
  • # of Trial Organizations: 59

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue